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Scarlet Fever has prolJa"bly caused more wide spread 
interest throu3h atte~pts at its prevention and serum 
treatment than any other infectiollS disease. However, 
in no other infectious disease has there been so much 
controversy among practitioners and at the same time 
such unanimity of opinion in the reports of experienced 
observers. Much of the work '.vi th serum therarY haYing 
been done "before adequate methods were adopted for pre-
paration, standardization and administration of the serum 
may account for some of the unfavora"ble res1)lts. Recent 
80nd careful investii.sators are much of the same opinion 
now in regard to the nse of serum in the treatment of 
this disease. Among the general practitioners and some 
teachers of theraDeutics there is still dou"bt as toorac-
~ .~ 
tical use of the serum. Because of tilis existing contro-
versy, I have chosen "The Serum Treatment of SC~l"-'let Fever" 
as my SU~Jj ect. By a survey of the 1 i terature on t'1i s 
topic, I hope also to "be the better enabled to decide on 
the meri ts of such treatment and to g~lin practica.l kYlOW-
led;e concerning its indications aYld ad~inistration. 
In a study of any disease one of the most interesting 
phases is its history, ["'),:ld for that re'-'tson I have included 
a "brief hi8toric~1 s~Gtch of Scarlet Fever. 
(1) 
D}5:B'rNITI01~ 
Scarlet Fever (44) is an acute infectious disease 
caused by Streptococcus scar1atinae, and is character-
ized by sore throat, a diffuse scarlet rash and the fre-
quent occurrence of a variety of complications and sequelae. 
The disease process consists essentially in a primary local 
infection from which a specific toxin is a~sorbed, and dis-
tri~uted by the blood stream. The specific toxemia is 
self-limited in duration. It ~ives rise to a series of 
symptoms, of which the rash is the most characteristic. 
The most important complications are of a seDtic nature, 
and are due to a spread from the primary lesion. The 
seqne1ae, of w~1.ich acute nephri tes is the most stri king, 
occur durincs convalescence ao!)ut the t1<li rd or -f'ourth week 
of the disease. The course and severi t:r of the seq'le1ae 
seem to be strikingly independent of the severity of the 
primary illness. 
HISTORY 
The works of Galen, Rhazes and other ancient writers 
contain various descriptions of a disease with throat 
symptoms and a diffuse red erllption slqgesting scarlatina, 
but not until the sixteenth century was the disorder 
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differentiated from measles by Ingrassias, of Naples. 
The first accounts of what appears unmistaka'bly to be 
scarlatina are those of Daniel Sennert, of Wittenberg, 
and his son-in-ltlW, Ivfichael Doerring, about 1625. They 
give us the typical descrlption of scarlatlna, the rash, 
desquamation, joint pains, anasarca. and delirium. 
Synde~~am in 1776, however, was the first to present a 
careful analysis of the disease with its medical charac-
teristics and to ~ive it the desi~nation scarla.tina or 
scarlet fever. He a.lso differentiated it from measles, 
with which it was constantly being confused. The epidemic 
7rhich gave Sydenham the opportuni ty for studying scarlet 
fever in large mmrbers was -eYidently a mild one, since 
he believed the disorder scarcely deserved to be con-
sidered a disease. But he was destined to change this 
"belief fifteen years later ;rihsn an el)idemic of unusu~,l 
malignancy, described by Morton broke out in Engla:'ld. 
Huxham (1740) appears to have been the first to call at-
tention to the importance of angina in the symptom com-
plex of scarlet fever (22) (5l)w 
The disease was common in Europe during the eighteenth 
century and from the middle of the era spread over "both 
hemispheres. According to Gaiger, it first appeared in 
the North American Colonies in 1735, spreadin3 over New 
England, reaching New York in 1746, thence extending to 
the coast states. By 1791 it made its appearance in the 
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interior, reaching Canada and the Northern States during 
the early :part of the nineteenth cent1lry. South Am~rica 
1;vas not invaded until about 1830, and sinpe then the 
disease has appeared often and at times in severe epidemic 
form, in nearly all of the countries of that part of the 
continent. During the middle of the nineteenth century 
scarlatina was reported from Polynesia, New Zealand, Tas-
mania, Austrailia and in distant Greenland and Iceland 
(51) • 
The recent history is more important from a standpoint 
of etiology. 
In 1885 Crooke reported the presence of streptococci 
in the blood and or3ans in fatal cases of scarlet fever, 
and Loeffer obtained streptococci from the throat in scar-
let fever, isolating the organism in pure culture. More 
striking were Kleins investigation of a milk born epid~mic 
of scarlet fever in Dendon near London in 1885. He iso-
lated streptococci in pure culture from a lesion in the 
udder of the cows, and also isolated similar streptococci 
in pure culture from the blood of scarlet fever patients 
during life and after death. He reproduced ulcerative 
lesions in cows with pure cultures of the human blood 
culture strains. He named the or~anism Uicrococcl1S scar-
latinae. In 1,399 Class, and in 1900 3aginsky and SOITL.'Tl.er-
field described the regular presence of streptococci in 
the throat, early in sc~rlet fever. The former infected 
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swine ~ith these organisms and o~served a scarlatina form 
r3>sh in these animals. Corroboratins Klein, He'Ktoen in 
1903, Jackman in 1905 ~l,nd others found streptococci in 
the hlood cultures during scarlet fever. In 1903 Schott-
muller introduced the method of eli fferentia tin~ betw'een 
hemoiytic and non-hemolytic streptococci. From then on 
it was found that it was the hemolytic streptococci which 
was so frequently associated with scarlet fever. Moser 
in 1902 and Savcheska in 1905 ir1IDunized horses with strep-
tococci obtained from scarlet fever patients in order to 
produce a therapeutic serum. The serums of both investi-
gators were used with a certain amount of success but the 
'fa"ITorable results could not be duplicated ge:1erally and 
the use of the sernm was a'Ja~1doned (44). 
In 1905 ,Tockmann p'l'Jlisned a re"ITie-n of the work done 
along these lines and examined the claims made that the 
hemolytic streptococcus so frequently fonnd in the throats 
of scarlet fever patients was the causative aJent of the 
disease. He came to the conclusion that a good case had 
not been made out and that this streptococcus was not the 
causative agent':)ut a secondary invader (36). 
In 1907 Gabrichevski published the results of his 
"fork wi. th a vaccine of killed cultures of streptococcus 
scarlatinae. He and his co-workers found that a large 
proportion of children inoc1)lated wi th the vaccine de-
veloped a marked erythefllia simil:'u to locali7.ed scarlatin9,e 
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rash and that a smaller proportion developed a train of 
symptoms indistinguishable from scarlet feyer. On sub-
sequent inoculation in the same subject reactions were 
less marked or absent. Gabrichevski held that his find-
in,];s clearly indicated t'u'3..t the sc"'slet fever stre}Jtococcus 
was a specific or,ganisIn, that his res;Jlts, taken with the 
fact that streptococc '"vere usually not obtained in blood 
cultures early in scarlet fever, proved tha.t the disease 
was a specific toxemia, and that streptococC 11S scarlatinae 
was the cansative aL~ent. Although his method of vaccina-
tion was used for a time in Russia with apparent success, 
his work was not carried further, but was over-looked or 
sliE~hted, until q1J ite recently. 7Tork on the sl1b,ject then 
lapsed and no important advance a.iJpears to have been made 
for some ten years. 
In 1917 Schultz and Charlton, experimenting with 
serum from convalescent cases of scarlatina, found that 
t~li s serum, when inj ected into the skin of acute cases of 
the disease, while the rash was well market, caused com-
plete blanching of the rash in a small area at the seat 
of injection. They also found that the Sertlm from some 
healthy individuals produced this result, whereas the 
serum from cases in the early stf:lge of scarlatina did not 
possess this power. This was a great step in advance, 
but was not so recognized at that time. In 1923 IvIair 
repeating these experiments of Schultz and Charlton 
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explained this rea,ction thus: "ScClrlet fever is ap1JClT-
ently a seneral toxaemic), and the rash only a rm.nif'estation 
of the toxin uni ting wi th the tis~me cells causing a capil-
lary dilatatj_on with swollen panillae. The serllm injected 
ne~ltralizes the toxin in the tissue and causes the disap-
pearance of the rash. The neJative reaction of the sera 
of acute cases of sC8.rlet fever is simply due to the fact 
that antitoxin has not yet developed (44). 
In 1919 Dochez, Avery and Lancefield devised a new 
method for the differentiation of bilo~ic types of hemoly-
tic streptococci. This led to a further study of the 
hemolytic streptocotcus so constantly found in the throats 
of scarlatinae patients. ~eports by Dochez and 31iss (19), 
Tunnicliff (46), and Stevens and Dochez let to the conclu-
sion that this hemolytic streptococcus was a specific 
type. 
In 1916 Dick and Dick (10) obtained ne~ative results 
in a serolo~ical study of the or~anisms found in the 
throats in scarlet fever patients. In 1921 they (11) 
inoculated human yolunteers 'ivi th the various orgcmisms 
derived from scarlet fever patients. Streptococcus scar-
latinae was probably among these bacteria. Some of the 
volunteers contracted a sore throat but none developed 
scarlet fever. In October 1923 the same 70rkers (12) 
published a second series of inoculation experiments in 
human volunteers with successful results. A culture of 
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hemolytic streptococcus, isolated from the infected finger 
of a scarlet fever patient was swabbed on the tonsils and 
pharynx of five individuals. After forty-eight hours one 
developed a mild but typical attack of acarlet fever; one 
had merely a sore throat and fever; three rem.ained well. 
Ey intracutaneous tests in human volunteers Dick and Dick 
(13) soon demonstrated a hi~hly potent toxin in bacteria-
free culture filtrates of streptococcus scarlatinae, the 
toxin which ·}a-brichensld had found in his vaccine of 
killed cultures. They then developed a number of new im-
portant facts regarding this toxin which they showed to 
be scarlet fever toxin. In January 1924 they (14) de-
scribed a skin test for susceptibility to scarlet fever, 
performed by intracutaneous injections of a standard amount 
of toxin. They(15) showed that an individ1)al, picked by the 
test as susceptable, developed scarlet fever on experi-
mental inoculation with streptococcus scarlatinae, while 
another control individual picked by the test as immune, 
remained well when similarly inocnlated. They (16) 
neutralized the toxin in vivo and in vitro by convales-
cent human serum and also with the serum of actively 
immunized huma,n volunteers. They(l?) found that individ-
uals, susceptable by their test, could be actively immunized 
with injections of toxin and these individu~ls then re~ 
acted negatively to the test and were immune to scarlet 
fever. In fact a series of 360 susceptiole nurses a~1d 
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internes actively immunized with the toxin, did not con-
tract scarlet fever on subsequent prolonged exposure, ten 
per cent of a control series of 240 nurses and internes, 
not tested or immunized, developed scarlet fever on sirnilar 
exposure. From this time on, the etiology of scarlet fever 
having been well established, most efforts we~e made to 
produce therapeutic serums for treatment and prevention. 
SERillill: THERA?Y 
All efforts to identify and isolate the specific 
cause of scarlet fever having fA.iled, it had ~')een impos-
sible to produce an immune serum for therapeutic purposes 
in this disease similar to that employed in the treatment 
tetanus, diphtheria, epidemic meningitis and pneumonia. 
However, it was naturally inferred that persons who had 
recently passed through an attack of scarlet fever would 
have specific antibodies in their blood, and should the 
antibodies be in sufficient concentration, that the serum 
of such blood might be of curative value when introduced 
into patients acutely sick with the disease. 
Acting on this presnmption, Weisoecker in 1897, 
treated five cases of scarlet fever with the blood serum 
of convalescents, but with little success. From 1897 
to 1903 scarlet fever cases were treated by injection of 
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convalescent serum "by lIuber and Blumenthal, Vcm Leyden, 
Rumpel and Scholz. They did not reach any ceitain conclusion 
as to the value of the procedure. The serum was injected 
subcutaneously and in relatively small doses. Because of 
the absence of any decided advantage from this treatment 
and from the fear of transmitting syphilis and other in-
fection the use of convalescent serum was aban~oned for 
a"!)out ten years. By this time the 'YEtSSermann test made 
it possi ')le to exclude syphilis from the donor of the ser-
um, and experience in the administration oflarJe quanti-
ties of serums had been acquired. :ntrav"enous injection 
of serum had also been successfully employed in 'Tarious 
cases. In 1912 Reiss and Jungmann treated twelve cases 
of severe scarlet fever by intravenous injections of 40 
c.c. to 100 c.c. of convalescent serum with marked benefit 
in ten cases. They drew the blood from convalescents about 
the end of the third or beginnin~ of the fourth week of 
the disease, tested each serllm for syphilis and sterility 
and mixed the serums from several persons, since some per-
sons seemed to yield lar.~er amounts of antibodies than 
others. The next year Kock reported from the same clinic 
the treatment of twenty-two additional cases with one 
death. He emphasized the value of early administration. 
He noted a prompt fall in fever nSll.ally followed 0y a 
slii~ht rise, and he was espec ially impre ssed "b:r the rapid 
and marked. imnroveme!lt in the general condition of the 
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patient. In 1915 Reiss and Herts, Rnd Kock reported still 
larger series of cases in which the results were most sat-
isfactory (49). 
In April 1915 Zingher (53) reported the treatment of 
scarlet fever with fresh blood from convalescents. In the 
fall of 1915 he reported the treatment of fifteen cases of 
very severe scarlet fever selected from 900 cases, with 
4 deaths. 
Zingher t s method consi sted in o"btaining fresh hUI'18,n 
blood (convalescent or normal) from a p8,reC1t or near rela-
tive, by means of a 30 c.c. record syrinJe and a needle 
inserted in the median cephalic vein at the bend of the 
el"'oow of the donor. The required arlOunt is rcq~lidly as-
pirated and i:rnmediately citrated by adding the blood to 
a 10 per cent sodium citrate solution in the proportion 
of 30 c.c. of blood to e80c11 c.c. of citrate sol1Jti6n, 
making a 0.33 per cent final dj.lution of the citrate. 
When the syringe is full, it is detached from the needle 
which is not removed, but is kept in place by an assistant 
who attaches to it a 5 c.c. record syringe containing a 
1 per cent sodium citrate solution to keep the needle free 
from hlood. In this way three or four syringefuls of 
blood can be obtained before it ~ecomes necessary to wash 
out the larze syrin~e with sodium citrate. Ihe blood is 
collected in 100 c.c. bottles, each of w~ich contains 2 
c. c. of sodium citrate solu"tion. To each t)ottle 60 c.c. 
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of blood are added. This is then s.haken to distrib'Jte 
the sodium citrate. The required 8.IDOunt, 120-130 c.c. 
can be thus obtained in less than ten minutes. 
The recipient is given intra~lscular injections of 
the blood (at one sittin~ into the triceps, the lateral 
region of both thi~hs, the calves and both sluteal re-
~ions; the dosase ')eing 15 c.c. for a youn'.; child and 
30 c.c. for an older child or an adult, at each of the 
three sites of injection. 
Two of the patients died from septic conditions, 
and the other two patients who died were mo!'i 'ound "vhen 
they were received. Of tb~ 11 patients who recovered, 5 
were of the purely toxic type, the other 6 had additional 
se:ptic complications. The 5 nnrely toxic cases shoYved a 
cri tical drop in tempera tnre after vfhich it remained nor-
malar slightly above normal. In the 6 remaining cases 
the drop in temperature was less marked and was followed 
by a secondary rise which persisted for a numl)er of days. 
In 1918 Weaver (49) reported the treatment of 19 
cases of severe scarlet fever selected from the cases 
that entered the Dnrand Hospital by use of the conval-
escent serum. His method was similar to that used by 
Zingher. The blood was drawn on the 20th to 28th day, 
using convalescent patients that were'free from S11spicion 
of tuberculosis and had nesative 'Yassermannts. The serum 
from several patients were mixed, tested for sterility, 
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Rnd stored, until used, in the refrigerator in portions 
for a sinJle dose. The serum was injected intrarnlscularly 
in doses of 25-90 c.c., 60 c.c. bein~ t~e usual dose. His 
results were favorable and coincide yith those of Zingher. 
Weaver (48) aJain in 1921 reports the treatment of 
54 cases of scarlet fever, 38 of the toxic type and 6 
septic complications, by use of intramusc')lar ser1Jm from 
convalescent patients. His results were very conclusive, 
Two of the patients died, one septic and one toxic, both 
bad risks. 
He presents charts showinJ the best drop in temper-
ature curve in those cases that 7lere ,.;iven serum earliest, 
Fourth week serum was preferred by him. Seventh week serum 
was found to be still activ~Mixed sero were best liked, 
D,inors ha,vj,ng mild attacks gave just as an efficient serum 
as those with severe attacks. Serums several months old 
were not as efficient as fresher serum. Bernba:lm (2) in 
reviewing the Ii terature reports th8.t Jvl. J. Synnott, l\few 
York, s 1lccessfvlly treated one case desperately ill, 'I'li th 
citrated convalescent blood. Temperature fell by lysis. 
lIoyne reports its successful use in the contagious hos-
pi tal of Cook County. C. Klin,,; and G. ';lidfel t, Stockholm, 
report the epidemic of scarlet fever that passed over the 
c1 ty of Stockholm in 1916-191?, 'vhen 2,165 cases 'lITere 
reported, showed a very large percentage of severe and 
fatal cases. Treatment of the severe cases by the serum 
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method prepared from convalescents was undertaken and showed 
excellent results. 3efore the serum treatment was attempted, 
the fatal cases of the severe form were 50 per cent or more. 
Of 237 cases treated, 195 proved successful and the percent-
age of deaths declined to 19.5 per cent in ~ecember and 6.3 
per cent for January, although the relative number of severe 
cases had increased. 7he serum prepared from the blood of 
convalescents 'lias found to be of equal value as taken from 
liJht, medium or severe form. The blood ~rvas usually taken 
from the fifth or sixth week after the first appearance of 
the disease, l)t1.t Vias found effective when taken the fourth 
or seventh w'eek. :::-1eal thy donors '!,rere selected. l~o second-
ary ill res'..ll ts were noted from the use of the sernm in any 
case. 
W. Schult/je, Germany, reports serum therapy was em-
ployed in 184 cases, the injection being either normal 
human serum, convalescent serum or mixtures of both. 
:F'avora:jle result s were secured, larger d)ses .;i vin~ the more 
definite improvement in the condition. 1he serum should 
be given within the first three days of the disease. 
H. F. Prinzing, Berlin, 1918, states that in patients 
1i'Tho had not received serum therapy, the disease 71£1S fol-
lowed l)y lymphadeni tis in 34.6 per cent, oy oti tis media 
in 10.8 per cent, and by glomeruler nephritis in 18.9 per 
cent of the cases. These conditions appeared in patients 
who had received serum in per cent of 15.9 - 9.3 - 8.2. 
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':7. Grissback, 3erlin 1919, reports thg.t i::1' Sl. study 
of 21 cases, human serum 'vas injected in 19 cases from 
convalescents, i::1 two from normal i::1dividuals; 10 to 20 
c.c. were given each patient. He ~tates qThe treat~ent 
is very efficient in modifying the duration and severity 
of the disease. ~he reactions following injecti6n of serum 
Are dan:;erolls." 
B. 3ernbaum (2) reported 39 cases by Dr. Levy at the 
meetin~ of the Detroit Pediatrics Society in the Hospital. 
Thi s 'Nas the number of cases treated at the Herman Fiefer 
~losrli tal wi th convalescent SentI'! for the year e~1ding July 
1, 1921. Thirty-two lived and seven died. Of the seven 
who died, t",VO were practically morL')und, one died within 
21 hours and the other 18 hours after entrance: one after 
ei~ht days of acute hemorrhagic nephritis, one after eight 
days of septic complications. Three died of toxemia. Two 
of these received but 10 c.c. of serum and one 20 c.c. 
Of the 32 who lived, 20 were toxic cases and 12 had 
Sel')tic complications. The average dose was from 10 to 
35 c.c. intra~lscularly. The serum was administered from 
the third to the eighth day of the disease. Children re-
sponded G,S ',vell as adul ts. :Ei;.:;h teen case s were treated 
so far the fiscal year, beginning July 1, 1921. These were 
the most severe of all cases of scarlet fever admitted 
since that date. Of the 18, 5 died. The blood was ta~en 
from healthy donors in the fourth or fifth week of disease. 
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-Snow and Fairbairn (37) in 1923 reported the cure 
of a grave case of scarlatinal sepsis 'Nith complications, 
in a. boy twenty-seven months old, by a blood transfusion 
from a six month's convalescent donor. 
Dochez (20) of New York described, in January, 1924, 
an antitoxic serum which he had produced in the horse by 
adopting a most inJenious method. In order to protect 
the streptococcus from the phagocytic action of the 
leucocytes of the horse he injected liquefied agar sub-
cutaneously into the horse f s neck, and 'vhen the a~ar had 
cooled and solidified, livin~ Streptococci scarlatinae 
were injected into the aJar. Thus protected the orzanisms 
~Irvived and produced toxin which was taken up by the 
l)lood stream. After a course of i1'l'1.Inunization of six 
months the horse was bled and the serum tested in the 
cases of scarlatina. 
Emplo;rin,~ this antitoxic sarurn, 31ake, Trask, and 
Lynch (3) obtained very good reS'll ts in t~1.e treatrlent of 
cases of sc;)'rla tina, a sin~5le intramuscular inj ection 
of the serum in early cases jeing followed by prompt dis-
appearance of the rash and symptoms of toxemia and a very 
rapid convalescence ,,'Vi thout complications. They f:nmd 
also that the serum, injected intradermally in cases with 
early scarlatinal rash, caused complete blanchinJ of the 
rash at the seat of inj ection (Schul t:;>;-Ch8,1"'1 ton reaction). 
They also demonstra.ted that t':1e toxin circulg,ting in the 
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Blood of acute cases of scarlatina is completely neutralized 
wi thin a few hours R.fter the inj ecti on of Dochez' s serum. 
They showed this hy bleedin;; the patient inu:nedi8"tely 1)e-
fore treatment and 0'0 aininJ positive Dick s~in reactions 
in suscepti ~')le indi vidn8.1s, g,nd ')y aTlin 'oleeding at fre-
quent short intervals after inj ection of D·)chez' s serum. 
Even in some very toxic cases the Dick tests were negative 
as early as four hours after the administration of the 
serum. 
In A"pril, 1924, the JhCKS (17) reported the prod'lction 
of an antitoxin in the horse by a different method. Their 
methods as descrihed by them is as follows: 
"The Strains of hemolytic streptococci that caused 
experimental scarlet fever in human 1)eings yield toxin of 
practically the same stren1th in all different lots, so 
that it is not necessary to standardize accurately 
prepared from these strains for immunizing horses. 
"Flasks of plain broth, containing I per cent sterile, 
def i or ina ted sheep f s blood, are inoc11l8, ted vri th pure c')l-
tures of the hemolytic Streptococci. Onr first horses 
were immunized with toxin obtained from plain broth clll-
tures,; l:mt wi th a small amount of 'blood in the broth, the 
toxin is somewl'la t stronger. We ha7e used hr oth p:-e}Jared 
! 
with 7itte's peptone, 1 per cent, and Lie~i3's meat ex-
tr8.ct, 0.3 per cent. After six days incubation, the cul-
tures. are filtered thrOl.1 ~h filter -;18,})er until clear, and 
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.!-, d t' , "D 1 .<' Id f"lte1" '_","'A st.Arl"ll"t~{ of \,nen :pas se n.rouJn a er Kel e .1" • u_ ~ - . ._ 
the filtrate is determined by cll1tllTe, and it is Kept in 
the refri:;;erator. Care must ~Je taken to discard any con-
taminated flasks before filtration. The sterile toxin is 
inj ected snocutane )usly in:~radually increasin,s doses, be-
ginning with 20 c.c. and increasin~ to 1 liter. The horses 
are then continued on injections of about 1,000,000 skin 
test do ses of the undi11 ted toxin every five days. 
"The sterile toxin does not ca~se abscesses and the 
horses r.enLain in :~\Jod condi tion •. After prelininary tests 
show that the horse is producing a good antitoxin, it is 
bled, and the serum or plasma is concentrated. The con-
centration is essential, not bec~use the antitoxin content 
of the unconcentra.ted serum is not high enou:;h, but to 
avoid unnecessarily frequent and severe sernm re('l.ctions. 
"An amount of scarlet fever toxin corresponding to 
1,000 skin test doses is capa'ile of causing general malise, 
nausea, vomi tinz, p. fever of 101 degrees F. and a general-
ized scn,rla tinal rash in suscepti "jle '],d1) 1 ts. In oPler 
words 1,000 skin test doses of toxin, if injected without 
previous immunization, prodllces a c11nic8,1 condi tion re-
sembling a mild attack of scarlet fever. We have ta~en 
the amount of antitoxin required to neutralize t"lis dose 
of toxin as a ~asis for the standardization of scarlet 
fever antitoxin. Any antitoxin used should "be of such 
strength that 1 d.c. of the concentrated serun will 
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'Nill Jleutralize 1,000 skin test doses of the toxin. 
is possi~le to obtain serum considera~ly stronger than this 
minimum requirement of potency. 
"Method of Standardizing Antitoxin: 
"For standardizin~, the concentrated antitoxin is 
d1lu.ted I to 10 in sterile 'Ph;rsiolo:",;ic sodium chloride 
solution. Two cubic centimeters of this diluted antitoxin 
is mixed with ~ c.c. of 8. toxin solution. -'-he solution 
of toxin used is 10 times as strong as the standard skin 
test solu.tion, so that each cubic centimeter represents 
100 skin test doses. 
"Tv>/'O control solntions are made, one of equal parts 
of toxin and salt sollltion, the other of' equ8l parts of 
the diluted toxin and salt solution. These three mixtures 
are incu~ated one hour. Skin tests are then made with 
0.1 c.c. of each mixture in persons with positive to 
strone;ly positive skin reactions. Persons 'vith sli:shtly 
positive reactions are not accepta~le for these tests. 
"On observation, at the end of twenty-four hours, the 
test made wi th the anti toxin alone ShOll.ld be nega ti ve. If 
this is positive, the person is sensative to horse serum, 
and is not useful for the standardization. £he test with 
the toxin alone should be .. • .+. • gosll,lve. The test with the 
toxin-antitoxin mixture will be neg~tive if the a~titoxin 
is sufficiently strong. 
"At the end of forty-eiJht hours, anoth~r observation 
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is made. The 'lVeaker anti toxin, like convalescent serum, 
rna:! hold the toxin in com.bination twenty-four hours, but 
release it after that so that the toxin-antitoxin test that 
was negative at the end of twenty-four hours may be found 
positive at the end of forty-ei3ht hours. 
'''For further standardb:ation, the same teets are re-
peated with higher dilution of the antitoxin. 
w;ie decided to employ as a therapeutic dose an amount 
of antitoxin sufficient to neutralize twenty times the 
quanti ty of tOlxin kno\I'{TI to produce the characteristic 
symptoms of scarlet fever in ad11l ts. }i'or convienience we 
speak of this amount of antitoxin which neutralizes 20,000 
skin test doses as a therapeutic dose. Each patient in the 
antitoxin series received one such dose, and in a few of 
the most severe cases, two therapeutic doses were given. 
"In their conclusions they state that injected intra-
muscularly, the serum '1lanch'3s the !'8.sh, lowers the tem-
perature and improves the general condition of scarlet 
fever patients. If given early it shortens the course of 
the disease and incidence of complications, and sequelae 
is greatly diminished. One therapeutic dose, as described 
above, suffices in early cases of moderate severity." 
'?li th the production of the DJchez serum a.nd that of 
Dick and Dick numerous inveGtigations were made immediately 
concerning their merits. 
In May 1925 Thene:)ee (40) repor+.,s favoral')le resnl ts 
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from the use of Dochez t s antiscarla tinal serum ;)y intra-
venous inj ec tions. In September, 1925, J:'heneo.ee (41) 
reports further observations on administration of Dochez's 
antitoxin in the treatment of forty-two patients. In this 
series of patients he used ':Joth concentrated 8nd unconcen-
trated antitoxin, by intravenous and intramusclllar injections. 
Se states that the unconcentrated antitoxin is the safer 
procedure for intravenous administration, 'rrfli1e the concen-
trated anti toxin is safer for intramuscula,r inj ection. 
3lake, Lynch and frask (3) and 3lake and Trask (5) in 
October, 1925, reported the treatment of 57 cases of un-
complicated scarlet fever; 48 cases of scarlet fever with 
septic complications, and seyen cases of post-scarlatinal 
sepsis, with Dochez's unconcentrated antitoxin by intra-
mlscular injection. The 57 uncomplicated cases were all 
promptly cured 'Ni thin 12 to 36 hours irrespective of the 
severity of the disease at the time of treatment. All but 
5 remained vvell: of these hvo subsequently deyeloped a 
mild non-suppurative cervical adenitis late in convalescence, 
one an otitis media, one a transient fibrinous pleurisy and 
one an acute nephritis. Of the 48 complicated cases all 
hut one were promptly and permanently cured of the specific 
toxemic phase of scarlet fever as shown ~y fall in temper-
ature, ra9id fading of the rash and prompt neutralization 
of toxin in the olood. 
1Hake (4) in July, 1924, reported concerning the ') se 
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of Dochez's serum as follows: "Intramuscular injection 
of the serum in therapeutic doses early in the disease is 
followed by ra}Jid clinical cure as evidenced by cri tical 
fall of temperature and pulse to normal, raJ)id fadin:~ of 
the rash Hnd prom:;::>t return to a state of well being. The 
specific toxic substance present in the blood of patients 
with scarlet fever is neutralized in vitro ~y Dochez's 
serum. It promptly disappears from the blood stream fol-
lowing serum treatment. ~he blood serum of scarlet fever 
patients acquires the capacity to blanch the rash in scarlet 
fever 7lithin a few houy's after serum treatment. Grah8.m (25) 
in usinz the Dochez serum had twenty-one patients de7elop 
serum disease out of thirty-one cases. ~ost of his patients 
were given serum after exposure to scarlet fever before 
symptoms had developed. 
Parks (32) October, 1925, makes the following report 
concernin:~ t:'le use of anti toxin: 
"Scarlet fever antitoxin was first administered by 
us in January, 1924. 1'his was Plade possL)le throu,sh a 
supply of serum by Dr. Dochez. The first serum was only 
moderately pbtent, and in the doses Jiven by the intra-
~lscular method, the results though sood were not strik-
ing. In January, 1925, it was decided to give it to al-
ternate patients, and in severe cases to 3ive it intraven-
ously. The antitoxin most used was our own preparation 
obtained from two horses that had received increasing toxin 
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injections for nine months and more; ~ut in about one 
fourth of the C~lses we used a new preparation of the serum 
sent us by Doche?,. The results of the intra'fenous injection 
was so striking that the medical ~oard decided . ~ ,. , In Jdarcn., 
1925, to~i 'fe all patients havin.:s a r:tsh and a temper'3.ture 
of 101 degrees F. or hi~her, antitoxin and to give it to 
alternate patients having a temperature lower than 101 de-
grees F. It was siven intravenously in all severe cases. 
:he potency of the antitoxic serum was tested either 
'by the Schulz-Charlton blanching test or 'lY the more ac-
curate Dick neutrali?'ation tests of the toxin. Its p'Jtency 
ranged from 50-150 units per cuoic centimeter; that is, 
1 c.c. of the serum neutralized between 5,000 and 15,000 
D~ck test skin doses of toxin. 
Most of the sernm was not refined. A')out fifty patients 
ho'vever, received the refined 8oYJ.ti toxic .;10')u11n sol'Jtion. 
The theralJeutic res'Jlts were =t1ike, hut re,shes occurred in 
about 60 per cent after the injection of the unrefined 
serum and in only a~'Jout 30 per cent after injection of the 
refined. ihe rashes and other symptoms of serum disease 
tha t did oc C'.Ir ";;ere more severe wi tn the unrefined. 
serious after-effects occurred in any case, ~ut the serl1ID 
siCKness in some was very annoyinJ. A sufficient dose 
should be 3iven at the earliest possible morne~t. An amount 
should he given i'1 the fi.rst dose to ffic-'.k-e ,cmd keep the 
fluids of the body anti toxic. :f, however, the tem)era tilre 
rises after the drop, a secohd injection should be given. 
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1he size of the dose is influenced by the weight of the 
individual and the severity of the case. Intravenous 
injections of sufficient size give the most strikin~ re-
sults. '';''he fluids of the ~)od~r "become qllickly antitoxic, 
as sho',"ln by the Dick test. 7his when done even an hour 
or tvw afterwR,rds, is al'f\rays negative, if a sufficient 
dose has beensiven, and rema.ins ne:r;ative if done later 
in the disease. 
The resul te from sufficiently large intramusc:Jlclr 
injections are certain, 'Jut they develop more slowly. The 
Dick test is positive for from six to twelve hours after 
. t 1" • t . T t t" .... an In"ramuscu ar InJec Ion. .L J nen ')ec()mes neJa.GIve. 
The results as noted at the bedside in the majority 
of patients are lTery stri ki:1~~."The hi!,her the temDerature 
and the more toxic the case, the more strikin~ will be the 
results if the serum is given very early in the disease. 
After an intraV'enous injection in an early uncomplicated 
case, the patient, as a rnle, finds within a few hours that 
the throat is less sore, the mind clears, vomiting ceases, 
the A<)I)eti te returns, 8.nd the temperature and pul se "oesin 
to fRll. 'Jithin from six to eL:~ht hours, C"t delirio:ls and 
a very sick patient is often conV'alescent. ith a larger 
dose ~iven intra~lscularly the same results follow, but 
more slov/ly. \,Hth ins1Jfficient dosaGe t1'H~re is less rapid 
improvement, and the toxic symptoms may retnrn. 
In 1926 Lewi s (31) reported favora~11e re 8'.11 t s for the 
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cure and reduction of complications in sc:=trlet fever by 
the use intramnscnl:l,rly of anti toxin. ~re thin'{s the intra-
venous injection is indicated only in critical oonditions. 
Stovall (39) in reviewing the advances in treatment 
of scarlet fever stated that the therapeutic value of anti-
toxin is established and constitutes the really well p~oved 
advCl.'Tce in its treatr'1ent. :a is effective in the cnre of 
the toxemia of scarlet fever and pro~ably indirectly lowers 
the incidence of complications in these cases. He states 
it should be used early in all cases of scarlet fever, hut 
it is only the occasional circumstance ~hich calls for its 
use for prophylactic purposes. 
In the treatment of 500 cases of scarlet fever, C11sh-
ing (9), u8in; both the Dtck serur:1~::md the Dochez serum 
intramuscularly, states that the disease is cut short and 
relief from all its early manifestations w~cs obtained. 
J!'rom his o"bservations he t:::links it lessens the number and 
severity of the comnlications and definitelv lo~ers the .!-. • 0..' 
mortality of the disease. He ~elieves the serum should "be 
used ec'lrly in every case except one~l~1.ich is extremely 
mild. 
Levy (30) in July 1926 treated 37 cases with scarlet 
fever antitoxin usin1 ~oth concentrated and unconcentrated 
serum. In severe and toxic cases they used intravenous 
injections and in the TIoderate cases intra~lJscu13r injections. 
Their results show the serum to be of value as a therapeutic 
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meaRure. They s ta te that serum sl10uld be .:~i ven earl~T be-
fore complications have occurred. In moder~te cases give 
intram~J.scularly and in severe or toxi c, intravenously. 
Also the serum sic~neBs is often more annoyin~ than the 
scarlet fever in mild cases. 2efore administerinj any 
forei3n serum they ~ive adrenalin chloride 1-1000 solution 
su"'Jcutaneo11s1y. They also Vfarm the anti toxin to body he!"tt 
and transfer to a glass lner syringe before injection. 
P. A. Bly (6) in 1926 reported concerning the treat-
ment of 34 scarlet fever patients ~y the use of the Doche~ 
serur:t and convalescent vlhole :)lood. He states that the 
serum appeared to ')rin,s about a more rapid improyement in 
the symptoms of the toxemia, and particl)l"lrl:;T an earlier 
disappearance of the exanthem. 
1)la tau. and Collins in Xovem"'Jer, 1926, rel)Orted 00-
servations over 100 cases of sC8"rlet feverifilich were 
treated with antitoxin. These are compared ~i~h a control 
;rOllp of 100 cases si:rrml taneously observed wr'licl"l received 
no serum. 71."10 of the concentrated comrnercial preparations 
were used. une made accordin~ to Dick's method, the other 
accordin3 to that of Dochez. ~ach patient receivinJ the 
antitoxin was .:;iven a sin,:,le "therapeutic H dose (10-14 
c. c.) as prepared ·by the ffic:mufacturer. All of the 8,nti toxin 
wasSi ,ren intramuscularly in dosages sufficie~'1t to neu-
" tralize from 200 to 500 thousand skin test doses of toxin. 
Intravenous administration was not done because of the fear 
\ 
of serious reactions. Rapid hlanchin1 of positive Dick 
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tests was noted after the antitoxin was Jiven. 
Serum react ions: Al thou:sh there '}'lere no iJYlJTIedia te 
anaphylactic reR.ctions noted, the urticaria and serum 
sickness, which developed in 25 of the 100 antitoxin cases 
must be considered seriously. Eleven of these were of the 
intense, recurrent type which persisted for three to five 
days and caused the most extreme discomfort to the tient. 
In eight of them, there WR.S a history of toxin-antitoxin 
administration fJur to fifteen "months before, and some of 
the most severe reactors were in a ;roup of nurses who pre-
viously had been immunized a:;ainst diphtheria. 
Toomey (42) in Decem':)er, 1926, reported the treatment 
of 345 cases, 300 ~)y intramuscular :mel 45 "by intrave"lous 
inj ecti ons, usin~~ a vari ety of the commerci3.1 preparati ons. 
Fifty cases were used as controls and did not receive the 
serum treatment. 
nThe reactions resultin; from the intramllscular injec-
tions were compara~le with other sera. SJIDe antitoxins cause 
more serum sic'(ness than others. "Ii th intramuscular inj ec-
tions, the serum reactions ranged from 10 to 70 per cent: 
dependent upon the antitoxin used. Chills occurred even 
vvith intramuscul(l,r inj(~ctions, 2nd h8,d the :.1.8112.1 sh"trp 
Tise in tempere_ture. This res"ltin.; sernr.'l sj.c1<ness vms 
re')ellious in nature, was h~.,rd to t8,>::e care of, n:'1d in 
some instances was even accompanied by edema of the epi-
~lottis and trachea, and ~y persistent vonitin]. In two 
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~nBtances (both nurses) the serum sic~ness was associated 
w'ith ma1'ked artnritis, dyslme8., cyanosis, 8.nd edema of epi-
glottis. :b'req11entl;r, the pain assoei:::~,ted '.I'lith S8rum sickness 
art:hri tis, overshadows +'he ~7'J.ole clinical picture, so that 
t·'ne - l' .... ... h ..~ . .J.. +.J" t t' 1 . 
- C01'1P leal·lon causes 'n e lJ8..iJlenl, ,,0 1.orge, ne (lSBel,se 
for ~hieh he has been originally treated. 
"7ith intravenous medication, ~e have ~een unfortunate. 
Abon t 54 cases were inj ected, ''on t the reac ti O:lSll\Tere so 
severe that we discontinued this met~od of treatment, hav-
ing 3 fatal cases ocenring 5 hours to 36 hours after in-
jection." 
Gordon (24) usin~ a concentrated antitoxin, prepared 
by the Dick method, treating over 300 cases mentions no 
difficv.l ty wi th serious reactions n,nd sa:;Ts th8t sCclrlet 
fever anti toxic serum exerts q favora'Jle and well marked 
effect in reducin~ the severity of the febrile stage of the 
disease, on the 'course '·md dura.tion of the fever, on the 
extent and duration of the skin lesions, qnd on the period 
of isolation. He states there are fewer cJmplications in 
pa tients receiving the serum, also a faYora,ble effect on 
cor.rplications evidenced l:>y a lessened severi ty a.nd duration, 
as ~ell as incidence. 
In January, 1928, ey reported 465 consecutive and 
unsel,"cted cases occnTrin~ at the Taillard :Parker Hospi tal 
in which 250 of the patients did "'lot receive anti toxin. :-Ie 
concluded that scarlet fever anti toxin is of defini te va,lue, 
-28-
out th'3"t the mild 8,nd l'10der,3,tel:r sick ~)[ltients do, not 
recr;iYe 8no11::;h "benefit to w'arrant its use. He also stated 
that the serum rash is often most distressing and causes 
more sufferinj than a moderate attack of the disease. 
Toomey (43) in N"ovembe-r, 1923, rej)orted that the mor-
tality rate of scarlet fever had not ~een lowered by the 
use of antitoxin. He refers to the fact that the mortality 
had dropped to its low rate ~efore the introduction of 
antitoxin and tha.t there had been no apprecia')ledecline 
either in hospital mortality rate or general rate in the 
years since antitoxin had been used. 
Place (:)3) in February, 1928, a"1d Pritchett and Fletcher 
(35) i"1 AU,sust, 1929, studyin3 the effect of a.ntitoxin stated 
that it had a definite favorable effect on toxic cases of 
scarlet fever but its effect on the complications were 
doubtful. Pritchett and Fletcher also stated that the ser-
um reactions are more severe than mild scarlet fever. 
'Jelford (50) studied the effects of antitoxin on 492 
cases of scarlet fever entering the 1funicipal Contagious 
Disease llospital at ChicaJo from January to June 1928. He 
stated that scarlet fever anti,toxin seemed to exert a "ben-
eficial effect in lessenin~ the toxemia of scarlet fever 
in 60 per cent of the cRses--classified as toxic or severe. 
During the period October, 1926-1927, Craig (8) treated 
500 cases of simple scarlet fe~er, 10 cases of septic scarlet 
~nd 2 cases of the toxic type of the dise~s2. 
ti ce f 011 o'vedwas to adni ni s ter sarnID, on the clay of ,,1"d-
mission to hospital, to every definite case of scarlet 
fever of the s:unple type within the first three days of 
disease. 
Sera from two different companies were used, and they 
in turn standardized by use of the Schult~-Charlton b1anch-
inJ test or the Dick test. A dose of 10 c.c. of the con-
centrated sernm was iSiven to each case intramuscularly. 
Serum reactioYls:- Ou.t of the total oL" 500 C8,888 re-
ceivinJ serum 41 per cent showed reactions at periods vary-
ing from 4-16 days after the injection. In no case did the 
symptoms Sive rise to alarm. ~n 25 per cent of these cases 
there was only a rash, which lasted from a ~ew hou~s to 
three days in the most severe cases. The remEdning 16 per 
cent showed definite si;ns of serum disease: slight pyrexia, 
adenitis, fleetin3 joint pains, and an urticarial eruption. 
They further state that the admirlistration of antitoxic 
serum within the first three days of disease produces a 
favorable effect on c ounteracti.ng the spec i fie toxeFlia. The 
full therapeutic dose should be given t=tt the earliest pos-
sible moment to obtain the best results. When ~iven ~ithin 
the first three days of disease it lessens the incidence 
8,nd reduces the severi ty of sU'Jseq1Jent complications and 
total period of hospitalization. 
"lurton and .....ialmain (7) S.3ptef'l;)er, 1929 used antitoxin 
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in the treatment of scarlet fever patients by intra~uBcular 
injections and oqtained favorable results. Tney state that 
the intravenous serum was not used ~ecause it was consid-
I 
ered unjustifiab~e to expose younJ children to R ~osBihle 
fatal therapeutic risk in a disease which at the present 
time is usually non-fatal. They state that Toomey and 
Dochez had three deaths wi th anaphyla.ctic symptoms out of 
40 ila tients inj eqted intravenously. 
Hill (26) iq October, 1929, stated the beneficial 
effects that may be expected by using serum in scarlet 
fever patients are a prompt subsidence of temperature, a 
quicker disappea~ance of the rash, a lessening toxicity, 
and perhaps the occurrence of a few less complications. 
He also stated that its chief value is in the treatment of 
severe cases. 
In l\fovember 1 1929, nick and Dick (18) report from thei r 
experience vii th ~carlet feyer anti toxin that it may oe em-
played therapeuttcally with advantages in all cases of 
scarlet fever as soon as the appearance of the rash sug~ests 
diagnosis. The longer the patient goes without antitoxin, 
the less benefits from it when it is ~iV"en. It should not 
'')e wi thheld until i t beco:!~es apparent that the a,ttack is 
a severe one, but should be given in time to prevent the 
development of a: severe attack. 
They state that reports as to the effect of scarlet 
fever antitoxin in reducing the complications are sometimes 
( 31.) 
----------------------------,----
~onflicting, due to delay in administering the serum in 
some cases, or to the use of poor preparations 
Gelkey (23) Octoher, 1930, stated that unfortunately 
the nel1tralize ... tion of i ts t~)xin does not 'prevent the hemol-
ytic streptococcus from further invasion. Se)tic Tn'oeesses 
are unmodified by the use of antitoxin, does not decrease 
the complications or lower the mortality becanse death is 
usually due to streptoc OC ell s i nvasj. on to other parts. 
Tsuda (45) in April 1931 gave a:1titoxin prepared by 
the Hygi eni c Research Inst i tu te, Sou th I\i~anc:1ur ia Haillivay 
Compcmy-l c.c. of this preparation is said to neutralize 
1000 sldn test doses of toxin. l{e gave llniformily 40 c.c. 
for an injection and stated that other writers are not 
definite about the dosage they have used. 
He further states: ":nvesti~ators hold different 
opinions in re3ard to whether the injection influences 
complications. Von J3orma:'1n stated that an injection at 
an early period prevents possible complications ~lt an 
inj~ction given five days after onset rna~es the patients 
more liable to complications. 3 enso '1 said th'l.t an injec-
tion renders complic~tions less likely; however, an injec-
tion on the first day of the dise8,se does not alwetys insure 
~ ~atient's not being affected by complications. According 
to Schottmuller injections reduced cases of lymp"hi'ldenitis 
"b:" half. Deicher sedd t:mt injections render complications 
less inte:lse, "but it is not certain whether or not the 
(32) 
injection prevents complicntio~s. Acc)rding to Toyoda's 
recent work the injection of an antitoxin seems to have 
little if any effect in preventin~ complications a~d to 
have no effect on complications already developed in the 
patient. 3uschmann also conside-red that an injection h~.s 
no preventive effect against complications." 
3anks (1) in a sUYlLmary of the results in 2,430 re-
ported cases of early uncomlllicated SC3rlet fever in which 
specific streptococcus anti toxin was used shows th8.t: (.a) 
Temperature recession is usually more prompt in the serum 
treated cases than in control cases. (b) The duration of 
the eruption is shorter in the treated than in the untreated 
cA.ses. (c) Early symptom improvement is more comm;)n in the 
serum-treated cases. (d) Desquamation is milder Rnd more 
loc''1li7ed in those '~lho receive sernm than i:1 those 'J'rho d.o 
not. (e) Anti toxin exerts a favorable infll1ence 0'1 the 
incidence of mnjor complications. (f) Intravenous admin-
istration of serum proba~ly ~ives the most striking thera-
pentic results. (g) Serum reactions Ci,re a I'1et1acil1~ factor 
in ab -mt ten per cent of cases Rnd can oe the cause of 
death unless the most rigid precautio:1s .3.re eml)loyed. 
Stevenson, Veldee, and Mitchell (3l) in the treatment 
of 196 patients oeserved the therapeutic efPects of SCRr-
let 84 }J3"tients constituted the control, 74 
the anti toxin A ;?:ronp 8,'1d 38 cornpri sed the anti toxin B 
:s:r Oup • Antitoxin A was purchased :a 
(33) 
'l,ras a concentrated seru.r.l prepared wi til 4 strains of hem-
olytic streptococcus, ori~inqlly isolated from scarlet 
fever patients. The therapeutic package WRS la~eled to 
contain 6,000 units of antitoxin in a volume of 15 c.c. 
However, because of an allowance for deterioration, each 
therapelltic dose ];iven contatned approximately 20 c.c. 
and possessed an antitoxin value of about 7,200 units. 
Antitoxin B was not for sale in the open market. It 
was an unconcentrated serum prepared from a single strain 
of' hemolytic streptococcns v!h~cn had previollsly been is-
olated from a case of scarlet fever. Test made at the 
~ational Institute of Health determined that this antitoxin, 
altholl::;h unconcentrated, CO'1 t~'d'1ed i~l the therapeutic dose 
of 8 c.c. approximately 6,400 units of antitoxin. 
The dvration of the period of eruption in the com-
bined antitoxin-treated groups Was 4.4 days, as aJainst 
6.9 days in the control group. 
Apparently, the antitoxin had no influence on the 
duration of the interval before desquamation began, nor 
did it halTe a pronounced inflnence 0'1 the desq1lamation 
period. There was a definite tendency for the desquamation 
to be localized and mild in character in the serum-treated 
ca.ses but to be ~eneralized aYld marked in the control 
patients. 
An analysis of the temperature records failed to re-
veal any definite febrile reduction followin~ an adminis-
tration of antitoxin. 
(34 ) 
3xcludin~ serum sic~ness, there were 75 per cent fewer 
otitis !:ledia, 
in the serum-
trea ted thc:J.n in the c antral 3r ouP. 
66.3 per cent of the serum-treated Datients developed 
serllm sickness of varyinJ de3rees of severity. 
A previous injection of serum seemed to 'oe the most 
imlJOrtant p"edisposin..:; cause of serum sic:Cness. 87.2 per 
cent of those tients who h:::td received a previolls i'1jec-
tion of hOTse serum in any form and 85.3 }J<:>Y ce-:1t of t:'lose 
'Nno had previously recei veel serum only in the fJrm of elilJn-
theria toxin-antitoxin developed serum sickness. 
In the ,3rouP of patient s \Y~lO had rece i ved no :lrevi ous 
injection of serum the total percentage of serum sickness 
-c~as 40.8. :n this~r()np the incidence of serum sickness 
seemed to be directly influenced "0y the volnme of serum 
injected, since 66.7 per cent of the patients receiving 
20 c. c. 0 f serum (anti toxin A) and 16.0 IJer cent of t:lOse 
reGeivin~~ 8 c.c. of serum (antitoxin TI) developed compli-I --
cations.. 
antitoxin over a period of 4 years. The se c(~ses include 
I 
those mentioned in ':1is previo:Js report (19~9). 
The ta~le contrasts between the cases t~eated in 1927, 
! 
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~This comprised in the average case (a) ~all of tem-
perature by crisis in 6 to 12 hours, (b) disappearance 
of toxaemic symptoms wlth7,eneral reeIiDs of well-being 
i""l 6 to 12 hours, (c) su')sidenceof fa'lCi'll oedeMA, in 
aeon t 12 hours, (d) fa.din; of rash in 12 to 26, hour s. 
\ 
'f'~rhen these effects are o'btained in any given case, 
certain SUbstantial advR.ntages follov/. The rapid arrest 
of the fever restores comfort and ~rin;s about almost irn-
Mediate return of appetite and normal Bleep. Ordinary 
diet is tolerated after 24 hours. T~ere is little, if any, 
loss of normal nutrltion, 8,11.d comralesce'1ce is correspond-
in,:;ly rapid. The patient IDa,;T then l)e safely allowed up 
after 4 or 5 days. 
"The rapidity with which faucial oedema su~sides is 
even more important. It appears, indeed, to ~e t~e key 
effect, and to ~e particularly associated with antitoxin 
admini stered in trayen.ously. As edema 6U ~)S ides, the pain 
(36 ) 
~ssociated with swallowing is relieved, Eustachian drain-
age 1S q'lickly re-esta~lis~ed, allowing middle ear inflam-
mation to resolve, a"1d the flow of se'itic material to the 
cervical ~lands is checked. 
'Pinally, the ra~id fading of the rash prevents Jes-
Q'WJl1Ettion. Desqnamation was e'1tirely absent 8 .. S n r'1le if 
the serum vva.S ,;i ven not later than the third d8.yo f the 
disease, a'1.d modified to a fine powdering, with or w:.thout 
small flakes 0'1. the h"'lJlds ~1.nd. feet, j.f administration of 
the serum 'vas delayed to the fourth or fifth day. 
II Reduction of Comnlications. 
----, .. _----------------«-----
lIComplications were reduced to a remarkable extent 
eVe!l 'vhen due a 110warJ.ce is made for the milder type of 
sct3"let fever prevalent in recent years. The fev\r compli-
c::3" t ions VI"li ch did occur were of ~3hort dura ti on and so mild 
as to leave no ascertaina~le ?er~anent damage. 
J' "'h " . 1 -. 1 1. e cyplca case, show1ng a norma response to intra-
venous serum treatment, shows no evident loss of nutrition, 
:10 desquamation nor complications, a"1d may 1)e discflE:rged 
from hospital after 8 to 10 days, or a few days longer, if 
it is considered desira~:)le that the patient s~10uld remain 
in hOSl)i tal over the period of the serum rash •• fI 
(37) 
"1.'he serum used was t:hR,t~)ut out :Jy the PRxk, :i)8vis 
a"1d Company and '3urrou~sh, '7ellcome and CompanY,--injected 
intravenously in adequate dosa~e; i.e., a s1n;le dose of 
approximately 20 c.c. for an adult, 12-15 c.c. for a c~ild 
6ver 10 years and 10 c.c. for a small child. 
Davi s serum appe::"red to have the advantaf~e in that no im-
mediate serum shock occurred in its nse. No anap:o.ylactic 
reactions in protein--sensitive or serum sensitive persons 
were met with in this series. The thermal reactions, with 
or without ri.sor,':-;(lich m;:l,J' occur about~, hour ai:ter intra-
venous i:'1jection, is in a different c:de;ory. It is cormnon 
and does not appear dangerous. :t occ'lY'red in 'h0th maKes 
of serum, the incidence varyinJ from 7 to 100 per cent, ac-
cordine; to the 'batch. It w'as al'Ifays treated prophylactically 
a"1d rarely gave rise to anxiety. In one case, however, 
(the only fatal case i"1 the series) it was associated with 
convulsive twitC:hL'L;, and death occurred 12 hours after the 
serum injection. 
"Generally it is of the utmost importance to obtain a 
se"um of proved ~)otency and known to oe free from trou"ble-
some reactions. Each new "batch of scarlatinal antitoxin 
used for intravenous injection in scarlet f'ever should 1:Je 
tested out in hospital in adequate dosage an a few cases 




lIAccording to the experience~ained i"1 this series of 
cases, the indications for intravenous injections of anti-
toxin in sCB,!'let fever wOllld, except :or the rare contra-
indicated cases, appear to be, in order o~ iMport~nce: 
1. T0xic scarlet fever. 2. Septic scarlet fever, even 
la te i"1 the di S98,se, provided tun t faue 1al edema iss till 
present. 3. The severe forms of sc~~latina simplex; ~. g., 
that conmonly OCCll,r in adults. 4. Defil1ite cnsesof scarlet 
fe 1rer wi.th faucial inflam..mation, rasll and pyrexia, espec-
ially those treated in a hospital ward along with other 
cases': 
CONTRA-IHDICATIONS 
ra) All cases ,;,vi th a history of asthma, eczema, hay 
fever, frequent urticaria or other manifestgtions of a1-
(b) All cases that have :'lCi,d a j)Y'evious in,jection of 
serum, especially within the previous two yea~8, except 
'Nhen serum is ur ;e:'1tly incU ca ted, in wni en case de sen-
sitization may be attempted. 
(c) Cas8Fl 'vhere any test for ser'lm sensiti1reness is 
llositive. 
(d) Very mild cases with little or no faucial , 
(39) 
inflammation and li ttle or no rash." 
!e~bE!.1:.9.ne: lThe con.junctival, intradermal and scari-
fication skin test for sensitiveness to the ~atch of serum 
to he employed, may be done as a preliminary, one dr~p of 
undiluted serum being used for each test. These are simple 
tests which can be performed in a !'1inl~te or two. The;v were 
employed d'lring the latter part of this investig8.tion but 
no serum-sensitive indivifulal was encountered. The first 
few drops of intravenous serllm should be given as slowly as 
possi 'ole, t~lis tec:':1nique cO:'1sti tnting a fourth test for 
serum-sensitiveness; viz., the intravenous test. In any 
case of doubt as to serum sensitiveness, the intravenous 
test in 1 in 10 dilution should be employed. A useful pro-
cedure in hospital cases is the suhc~taneous injection of 
1 c.c. horse ser1lID by the Wlrse, one hour before the intra-
venous in.jection~ 
"'iTi th all new batches of serum, adrenalin should '::le 
injected subcutaneonsly just before giving the serum. 
This prophylactic adre'1alin may be given in all cases as 
a routine, but it is, as 8, rule, unnecessary vrhen ade-
quate experience of a particular lJatch of serum h8s 11een 
:After this procedure the serum is inJected undiluted 
int 0 a vein "by t1:1e syri nge JTlet~lod--be s t us i ng 8. short 
rigid needle 'Hi th a short :)eve1, a sharp point, and 
about SilO TI. m. '::lore. After the injection, 
(40) 
the foot of the bed is raised for an ':l)11T, the p8.tient 
being wrapped in a warm blanket, and hot ~ottles put into 
the oed:' 
Joepehen (28) calls ~ttention to the fact that opin-
ions a:)out the serotherapy of sC;:-l,rlet fever are still 
divided. J oepehen l1'lade (1)serva t ions on 220 case s. Of 
these, 100 were treated with intravenous injections of 
serum, :::;0 with normal horse serum, and the Jther 100 re-
ceived no serotherapy. He reaches the concl 11sion that 
intravenous seroth(3rapy vii th srY!E\,ll doses fifty be recommended 
and that it has advantages over the intra~lscular method. 
However, it influences only the initial toxicosis, the 
exanthem and the fever, and does not prevent complications 
or reduce their severity. For tais reason Joepehen employs 
serotherapy only in the toxic and severe cases, and he 
emphasizes thc~~t the injection should "oe nade as ea""'ly as 
possi")le. 
Kahn and Josey (29) are of somewhat the same opinion 
in regard to Ule serum therapy. :::n an a~'1alysi s of ?02 
cases of sCRrlet fever in adFlts a"ld olcier childre:1, of 
whom 127 received antitoxin, the report shows a definite 
favorable effect on the toxic svmptoms o~ th~ disease. 
'l'hey state the hi:;h i:1cidence of disability d:Je to serum 
cliserlse must lJe wei~hed a,::;ainst this effect. The incide:~1ce 
of complications is not affected by S8rHID admini.stration 
8.1tholl~~h their severi ty may lJe lessened. 
(41 1 
in a study of 2,303 cases 
of scarlet fever in which 88~ wer~ treated with antitoxin 
of the disease Rre the early diagnosis a~d the ~dministra-
tion of an adeq~w .. te 8 ...mo'J.nt of sC[lrlet feyer anti toxin. The 
Cl.n ti toxin used was a c )I'1Jnerc 1"11 C O"1cen tr::l ted 8:1d reP ined 
serum, standardized by means of skin tests in sllscepti'b1e 
~)ersons. Une therapeutic dose (sufficient a:1ti toxJ_11 to 
neutralize 300,000 skin test doses of toxin) was ~iven 
intram.uscularly in MOS t cases, 801 thou",.:;h in some of the 
severe cases two, three, fOllr or mo"e therapeutic doses 
Of the effect of anti toxin on the cli nic8"1 course of 
the disease }Iunt states: ":f enouJh antitoxin has been 
~i\Ten, the typical punctate rash fadesNi tilin tW'elve to 
twenty-four hours q,nd fiFty be absent/vi th:mly 8 .. S11bcllticu-
lar flush per~isting. If the rash h~s been pres?nt for 
three or fDur days, the effect of the antitoxjn on the rash 
is not so stri king b11t it ha.s a tendency to run a course 
somewhat simillC1 .. r to the r;::csh in ca,s!~s in 'J'hich a'1ti toxin 
has not been adEinistered. Corroborative evidence that 
the s~in lesions are milder is shown by the fact that the 
clesree of desqnamation is ma,rkedly less in:Jatients re-
ceivtn~ antitoxin, ~eing usually s1i~ht a~d lasting somc-
tlmes for only a few days. ".'Ji t:'l the disal)pearance of the 
ras~ there is a marked improvement in the seneral condition 
(42) 
of the patient, especially noticea~le in toxic cqses. 
Another effect of the anti toxin is the l.mmn,skino; of s11ch 
complications as are already present. ihe removal of the 
toxic element of the disease makes the recoJnition and 
proper treatment of early complications more certain. 
In regard tJ cOI'1plications he stated (1) A l:''),r:?;e 
nnm"ber of ser i ous campli CR. ti ons occurred i:1 t:ae mild ce,se s 
in ""Thich anti toxin 'Has not adrcinistered. 
humoer of severe cases were free from c ,)mDlications in the 
series in 7rhich cmtitoxtn was administered, in contrast to 
the L3er;e num-oer of severe C3,se s 1-,11.,q t sho'Ned c ornpli cat ions 
in the series in which antitoxin was not ~d~inistered. ( 7, , t,...J ! 
A sma.ll num'ier of complications occurred '7hen the a:1ti toxLn 
V\To'loS given durin.:; t~'1efirst two or three days of the disen.se. 
Illustrative Cases of Septic and Semi-septic Types (1). 
'7. :;t., Mal e , admitted lO-28-30~ notified 
~he c~ild was drowsy and extre~ely ill: 
temperature 102.? de.~rees F.: .lJ111se 116: T2S"D. 2B: sli:~ht 
:lllJuminuria. Ins?ection of the throat showed intense 
oedemF\. of fauces and. soft l)al:),te l[vi t:::l extensive sloushing 
111ceration of tonsils, pill';:,.rs a'1d Hyula, and copious 
mue 0 -purulent naso-pharyn~eal d i sc'1ar3:e. 'the cerirj, cal 
(43) 
..• --------------------
:r18.nds were grei\tly enlar.;ed, pD.rtic'1htrly on the right 
side, .qncl there W'.3>S some peri;landular oedema.i'he ton:;ue 
was of the Hred stra;',berry!l type. A sC~Hlet fe'.Ter rash 
was present, faintly marxed O~'1 the tr'Jnk 'Jut mOY'e defini te 
on the limbs, 'Nhere it Vh'cS of the II !Jlotchy·t ChclT"lcter so 
often associated with sepsis. The case appeared to be a 
typical scarlatinal anginosa. Treqtment on admission: 
7 c.c. scarlatinal antitoxin intravenously, and 12,000 
v.ni ts diphtheria anti toxin intramuscularly, toi;ether wi th 
routine irrigation of f8,11Oe8. Hext mor'1h1:~ the throat 
8 71'"a"o proved to lJe nega~ive for diphtheri"), 1)8.oilli: f8..'lcial 
oedema 7iT(l,S ';1;rea ted reduced ,bu t as t'.:le cIli Id was still '[ery 
ill an additional 17 c.c. of scarlatinal antitoxin was 
given intravenously. ~he same e7enin~ the general condi-
tion sho'wed ma"ked improvement, f3,'lCi,"1.1 oedema had almost 
disappeared, althou~h there was deep and extensive ulcer-
ation; temp. 97.4 deJrees F., pulse 108. Next morning 
. 
10-30-30 fa,11cj.al oedema was nil (36 hours) 'lYld '1asal dis-
Cht1.rge had cle'1.red IIp. J:'er:1perature remained normal from 
24 hours after the first close of serum, exce)t for a rise 
to 100 desrees F. on -l:;he f onrt'1 da'l after adT~i s s ion. tTI' ine 
was albumin-free 48 hours after aclmission. rhe fWlcial 
ulcer:Jtion lvas practically h:~aled in 6 da~ts. A SerH:r:1 rash 
was present from the sixt~L to the eleventh day aft(~rad-
mission. The child was allowed 11.p on the fifteenth da;'t 
8.Yl(1 was disc:!iar.::;ed well after 25 da;'Ts in hospi tal. 
(44 ) 
Cp,se II Senttc type sixth da~T. __ .. ____ .., _______ ._.A..--__ ~_ .... _~._ ....... ____ ________ ...,.;... __ 
H. G., meole, age 5 ye,:,rs; admitted 3-l5-'~9i gr83ely 
ill~ -restlessj delirious! sel'li-cc)matose. Fa,ucLlloeder:lcl, 
wn,s ex-':,reme, the f8,1JCeS Y'1ee+-tng j_n the middle line~ copious 
pnrrtlent nasal dischar::;e; cerlTical ,~1':v'1ds enlarged to form 
pR.]illae; rash faded~ temp. 
p';lse uncountq,hle; cY'3,no;:;is rrlarked_ at times wi th impr:rcept-
i~le ~ulse. Treqtment: 20 c.c. scarla:i1al antitoxin 
intra'lrenollsly; stiY'1'llants (caMphor 90nd e:~er) oxy~en, and 
3ravely ill and not fully conscious; rash petechial in 
character; crepitations at bases of lunJs; oedema of throat 
sli,;htly reduced, allo'vin:; \)re'lthing to be e8sier: profuse 
p'lrnlent di schar~e from nose ~md throat; piece of 
necrosed tissue douched out from throat; bowel washed out 
-rrith ~;ood results, On 11arch 17, 36 hours after admission, 
temperature was normal, pul se 106; conrli ti on 1'1!C1S :;re"1._ tly 
improved; child could anS7ler que sti ons; 6landular swelling 
greatly reduced; colour and :;)1).1 se (pit e ~;ood. 24 hours later 
he was qlli te comforta,l)le; fancial and periglandlllar oedem8, 
had disal)peared, althol1;h lllceration was still exte~'lsi'Te~ 
a lar-~e ell. Berete :;land could 0e felton left r;ide of neck 
~-tnd a few sI'laller-;lands- on ri;ht side. Ter:rperat 1)re rose 
a~ain on third eveninJ after admission and reI'lained elevated 
( 45) 
~hi1e a ~l~~d a~sce8s slowly formed on left side; tais 
was incised on March 2~nd Rnd R similar gland abscess on 
ri~ht side was incised on ~arch 25th. The child was dis-
charged well after 41 days in hospital. ~. B. In these 
two severel~r septic cases, otitis media did not develop. 
C. B., male, aee 4 vears: '-i.dmi tted ,3-21-30 ~ child ill 
·~vi th mar1{ecl p;:tl10r and restle,'s.'1ess~ i:1te':1se oecleY'1a of 
to,1silzi , palate 8.nd uvulC'", vlTith pult~:tceons exudate covetr"lg 
~)oth t ansi 1 s, pro fu se pUTulent net. sal cii sCflc~rge, and marked 
adeni tis; !Ired strawberr:"r il tongue ~ faded Y'ermants of rash~ 
temp. 100.2 de--;rees J?, pulse 1:56. Trerl.tf"lent on adr:,ission: 
20 c.c. scarl~tinal antitoxia intravenously, irrigation of 
fauces, etc. Next morning general condition excellent; 
fauci8.l oedema nractica1lv di ~ - - - .. - e~ .. re(l ; 
deep 8.nd extr:>nsiITe ulcerated area involv-in; ';'lhDle of tonsil, 
pillars, and uvula and covered with pus; adenitis reduced; 
throa t swab ne ~s8.t i ye for eli})h theria 'Jae il1i • Tel"'lperR.ture 
remained normal throu-~hout this a cla~r, then rose 8_~8.in, 
and ::;r8.dllally fell to norp'tal oJ;ring next 6 days, 'Jl~lile the 
ulcerated s]1rfaces healed; the general condition remained 
:sood throu:~hout this period. This case desTJamated t;,'-pi-
cally and was discharged well after 38 days in hospital. 
seventeel1th da'- . ')f scarlet fever, which had follo'lVed ~)nrns 
of the forearm and a~domen on 1-13-32. On admission, there 
. ~. .. t . '1 
was In "ense InJ ec 1 0~1 ana 08CAemR of fanc2S,palate and 
pharynx, the tonsil meeting, and the '/lho Ie qr2a ~)e i ne 11,1-
cerated Rnd covered with pus; profuse purulent nasal dis-
char,;e Ftnd marl<E-?6 r:ervi cal adeni ti s; resp1 rat ions rapid 
and noisy; dyspnoea and dysphagia ~rom obstruction in throat; 
the dlild was desqnarrJ.atin:r typic8.,1, "ritll flakeF'· or slein on 
I 
"'emp. 101 rle'~recs J?, pulse 140. 0erum was not 
-iven,on admission owing ~o the late stage of the disease. 
On 2-7-32, the child vIas 0 bvi oHslYsoing d')'vvn~1ill: dyspnoea 
was c~ntinuous, and feedirtg was almost impQssi~le; oedema, 
i 
ulcer$tion and discharge was, if anythinj, worse. The 
! 
prognfsis was grave, cl,Y1d it was decided to try the effect 
I 
of intravenons antitoxin, 20 c.c. of ,r(nich ',7"1,8 gJ_ven on 
Six honrs later, iml)rOVement was observed ~ the 
child: sat IIp Emd talked for the first time. 
I 
In 36 hours 
i 
a-f'ter! the injection of serum, the fO.u.cial 'yedema '18,0. ::11-
most ~ll disappeared; there was no dyspnoea and swallowing 
~as e~sier; the throat was much cleaner and 
I 
extensively 
]Jlc ed area cO'11d ~e easily seen for t"1e fir:::.t time; 
per e remained normal f or the next 24 [lOUr s, then ro se 
owing to otit's medin. Left ear discharzed on 
(47) 
Febru8,ry 13th. Serum rash 7vas trou\)lesorne 0"], :b'e1Jrnar;;T 16th 
'1nd right ear di schar;ed on Febr 118,ry C) 7th. 7he ral ) C ial vl-
rieratioh was healed on February 14th, ? days after admin-
istration o~ serum. The child was dischar~ed well on March 
23rd, after 50 days in hospital. 
K. C., female, a?;e 19 years; admitted 10-0-30, in 
sixth day of the disease~ fauces oedematons 2tndextensi'lely 
Hlcer~lted; profnse post-nasal pnrulent disch8,rge; TnB,rked 
adenitis; "red strawberry" ton~ue; remnants of faded scar-
la t inal eru:Dti on pre 8e~'1t. The si 1"'1 ,cras lP1comf or t('l.ble, had 
not slept for several ni,;hts, and had considera"ble pain on 
57ralloYling. ''':emlJ. 101.2 :F., lYulse 110. 'rreatment ~~O CoCo 
scarlatinal antitoxin intravenoHsly. Next morning she felt 
"ever so much betteI"l; fauctn,l oedema was rnarkedl1T red1Jced; 
there '[vEl.S no pain on 6'][9,110wing, al P10T;h the fallcial 1)lce1'-
+" 8.:, 1 on \flaS still exte"1sive: <Hl en i tis ron c h red u c e d • .J.eT1per-
~ture became normal on October 11th and O~ October 13th the 
f8,1).ces "vere q11i te hea,led and she vms allo",,"led UP. She des-
quamated freely. She was discharged well on Octoher 21st, 
after 15 days in hospital. 
(48) 
-COKCLUSIONS 
1. Scarlet fever antitoxin exerts a favorahle in-
fluence on the clinical course of the disease. T"his is 
evidenced by a lessened severity of t~e febrile stage of 
the disease, on the conree ~,nd durqtion of the fever, and 
on the extent and duration of the skin lesions. 
2. Antitoxin exerts a favorable influence on the in-
cidence of major complications. 
3. Most of the complications that occur in patients 
who have recei~red anti toxin, appear to be in LlOse who have 
received it relatively late in the disease. 
4. Serious cJmplications often develop froM mild cases 
of scarlet fever treated without antitoxin. 
5. Intravenous administration of the serum pro"b'1,oly 
gives the most strikin~~ therapeutic res~llts. If 8 ~ood 
preparation of' serum is used, intrayenons medication is 
apparently just as safe as the intrar1nscnl;"1,r. 
6. Serum reactions are a menacinJ factor in many of 
the cases, depending in part upon the serum used and in 
part upon the sensitivity of the ~atients. Ev~r~ patient 
should be tested for sensitivity before the serum is given. 
(49) 
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